La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NeoGenomics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Chris Smith

Amministratore delegato

US$11.7m

Compenso totale

Percentuale dello stipendio del CEO	8.6%
Mandato del CEO	2yrs
Proprietà del CEO	0.5%
Durata media del management	1.9yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Smith rispetto agli utili di NeoGenomics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$12m	US$1m	-US$88m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$15m	US$346k	-US$144m

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 11.67M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Smith (61 yo)

2yrs

Mandato

US$11,665,946

Compensazione

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Smith	CEO & Director	2yrs	US$11.67m	0.53% $ 11.4m
Jeffrey Sherman	Chief Financial Officer	1.7yrs	US$3.55m	0.12% $ 2.5m
Vishal Sikri	President of Advanced Diagnostics	2.6yrs	US$2.37m	0.10% $ 2.2m
Melody Harris	President & COO of Informatics	1.7yrs	US$4.69m	0.085% $ 1.8m
Warren Stone	Chief Commercial Officer	1.8yrs	US$3.01m	0.079% $ 1.7m
Gregory Aunan	Chief Accounting Officer	1.3yrs	Nessun dato	0.011% $ 242.1k
Kendra Sweeney	Vice President of Investor Relations & Communications	no data	Nessun dato	Nessun dato
Alicia Olivo	Executive VP of Business Development	2.3yrs	Nessun dato	0.035% $ 751.3k
Hutan Hashemi	Chief Compliance Officer	2.3yrs	Nessun dato	Nessun dato
Derek Lyle	Chief Medical Officer	3.6yrs	Nessun dato	Nessun dato
Gary Passman	Chief Culture Officer	1.6yrs	Nessun dato	Nessun dato
Fernando López-Díaz	Director of Clinical Science	no data	Nessun dato	Nessun dato

1.9yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di NEO non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Smith	CEO & Director	2yrs	US$11.67m	0.53% $ 11.4m
Michael Kelly	Independent Director	4.1yrs	US$317.50k	0.025% $ 531.9k
Lynn Tetrault	Independent Chair of the Board	9.2yrs	US$365.00k	0.048% $ 1.0m
Bernard Fox	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato
Riccardo Dalla-Favera	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato
Anthony Zook	Independent Director	1.2yrs	US$276.23k	0.0089% $ 190.0k
Steven Rosen	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato
James Downing	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato
Stephen Kanovsky	Independent Director	7.1yrs	US$309.20k	0.028% $ 604.5k
Razelle Kurzrock	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato
Alison Hannah	Member of Scientific Advisory Board & Independent Director	9.2yrs	US$305.00k	0.093% $ 2.0m
Mark Rubin	Member of Scientific Advisory Board	3.6yrs	Nessun dato	Nessun dato

3.6yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NEO sono considerati esperti (durata media dell'incarico 3.6 anni).

NeoGenomics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

Recent updates

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock

Price target decreased to US$19.45

First quarter 2022 earnings: EPS misses analyst expectations

High number of new and inexperienced directors

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022